{"url_path":"/sec/mcrb/8-k/2026-07-08/item-1","section_key":"item-1","section_title":"Item 1 Election of three Class II directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-08","source_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","accession_number":"0001193125-26-298525","cik":"0001609809","ticker":"MCRB","issuer_name":"Seres Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","primary_entity_key":"0001609809","primary_entity_name":"Seres Therapeutics, Inc."},"word_count":55,"has_tables":true,"body_markdown":"Item 1 - Election of three Class II directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.\n\n \n\nNOMINEE\n  \nVotes FOR\n  \nVotes WITHHELD\n  \nBroker Non-Votes\n\nStephen A. Berenson\n\n  \n3,690,033\n  \n426,428\n  \n868,715\n\nClaire M. Fraser, Ph.D.\n\n  \n3,825,690\n  \n290,771\n  \n868,715\n\nRichard N. Kender\n\n  \n3,824,452\n  \n292,009\n  \n868,715"}